Literature DB >> 23870631

Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.

Martin J Holzmann1, Ulrik Sartipy.   

Abstract

Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG). We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG. From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden. The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG. Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders. During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths. In total, 17% of patients developed acute kidney injury postoperatively. Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model. The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders. Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23870631     DOI: 10.1016/j.amjcard.2013.05.077

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Current outcomes of off-pump coronary artery bypass grafting: evidence from real world practice.

Authors:  Piroze M Davierwala
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Impact of mild preoperative renal insufficiency on in-hospital and long-term outcomes after off-pump coronary artery bypass grafting: a retrospective propensity score matching analysis.

Authors:  Qiang Ji; LiMin Xia; YunQing Shi; RunHua Ma; ChunSheng Wang; YunQing Mei; WenJun Ding
Journal:  J Cardiothorac Surg       Date:  2016-02-18       Impact factor: 1.637

3.  Ventricular Dysfunction in Patients with Acute Coronary Syndrome Undergoing Coronary Surgical Revascularization: Prognostic Impact on Long-Term Outcomes.

Authors:  Batric Popovic; Nelly Agrinier; Damien Voilliot; Mazen Elfarra; Jean Pierre Villemot; Pablo Maureira
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

4.  Comparison between three different equations for the estimation of glomerular filtration rate in predicting mortality after coronary artery bypass.

Authors:  Sandro Gelsomino; Massimo Bonacchi; Fabiana Lucà; Fabio Barili; Stefano Del Pace; Orlando Parise; Daniel M Johnson; Michele Massimo Gulizia
Journal:  BMC Nephrol       Date:  2019-10-16       Impact factor: 2.388

5.  Improvement of cardiac function after coronary artery bypass grafting surgery reduces the risk of postoperative acute kidney injury.

Authors:  Jiarui Xu; Xin Chen; Yeqing Xie; Jing Lin; Wuhua Jiang; Jiawei Yu; Yimei Wang; Zhe Luo; Chunsheng Wang; Xiaoqiang Ding; Jie Teng; Bo Shen
Journal:  Clin Cardiol       Date:  2022-01-30       Impact factor: 2.882

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.